Premium
Bumetanide—The Way to Its Chemical Structure
Author(s) -
FEIT PETER W.
Publication year - 1981
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1981.tb05661.x
Subject(s) - bumetanide , diuretic , furosemide , sulfanilamide , loop diuretic , thiazide , chemistry , pharmacology , carbonic anhydrase , endocrinology , medicine , sodium , biochemistry , enzyme , cotransporter , organic chemistry
The steps in the evolution of sulfamoyl diuretics in current clinical use are outlined. The development was initiated by the chance observation of a clinical side effect of sulfanilamide, which became the first sulfamoyl group (‐SO 2 NH 2 )‐bearing compound used for diuretic treatment of patients. Ensuing chemical synthesis over the past three decades led to the development of three types of sulfamoyl diuretics: carbonic anhydrase inhibitors, thiazides, and the loop or high‐ceiling saluretic agents represented by furosemide and bumetanide. The structural relationship of furosemide to sulfanilamide and the thiazide‐type diuretics and, for bumetanide, the more specific structure for loop diuretic activity are discussed.